FabiFlu Drug launched for moderate COVID-19 cases
Glenmark Pharmaceuticals Limited has announced the introduction of Favipiravir under the brand name FabiFlu in tablet form for the treatment of mild & moderate coronavirus (COVID-19) cases in India.
Nearly 80% of all COVID-19 positive cases in India are under this category. FabiFlu is India’s first oral antiviral drug for the treatment of mild and moderate COVID-19 patients, the company said.
“It is a significant step in the fight against COVID-19 India. Glenmark is leading the flight. We are not looking at it as a business opportunity. The priority is to make the drug available to as many patients and save lives,” said Sujesh Vasudevan, president, India Formulations, Middle East and Africa, Glenmark Pharmaceuticals Limited in a video conference.